Highlights Biotron Limited

Equities

BIT

AU000000BIT4

Delayed Australian S.E. Other stock markets 11:08:26 20/05/2024 am IST			5-day change	1st Jan Change
0.055 ^AUD	0.00%		-5.17%	-43.30%

05/04	Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25%	MT
26/02	Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25%	05/04	MT
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Biotron Secures Nearly AU$2 Million R&D Tax Rebate in Fiscal 2023	08/02	MT
Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/23/25	CI
Biotron Secures Second Site for COVID-19 Trial	12/23/12	MT
Biotron Begins Phase Two COVID-19 Trial for Antiviral Medication	04/23/04	MT
Biotron Limited Announces Completion of Phase 2 HIV-1 Clinical Trials	09/23/09	CI
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2022	17/23/17	CI
Biotron Receives $958,000 R&D Tax Rebate for Drug Development Programs	18/22/18	MT
Rights Issue: 1 new share @ 0.03 AUD for 5 existing shares	31/22/31	FA
Biotron Completes Enrollment for Phase 2 HIV Trial; Shares Jump 7%	04/22/04	MT
Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2022	19/22/19	CI
Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	21/22/21	CI
Biotron Secures US FDA Guidance for COVID-19 Antiviral Drug	30/22/30	MT
Biotron Limited Receives Positive U.S. Food and Drug Administrations Guidance for COVID-19 Clinical Program	30/22/30	CI
Biotron Limited Announces BIT225 Effective Against Established SARS-CoV-2 in Animals	02/22/02	CI
Biotron Receives $1.2 Million R&D Tax Rebate	05/22/05	MT
Biotron Limited Announces Confirmation of Bit225 Effectiveness Against Covid-19 in Animals	17/22/17	CI
Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2021	23/22/23	CI
Biotron Limited Announces Its Lead Clinical Asset, BIT225, Demonstrated Substantial and Clinically Meaningful Efficacy Against SARS-CoV-2 in A Series of Animal and Cell-Based Studies Performed At the Scripps Research Institute, La Jolla, CA, USA	25/21/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biotron Limited

Equities

BIT

AU000000BIT4

Highlights

Filters